<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088383</url>
  </required_header>
  <id_info>
    <org_study_id>Rev0</org_study_id>
    <nct_id>NCT04088383</nct_id>
  </id_info>
  <brief_title>Amnios™ RT Outcomes Study</brief_title>
  <official_title>A Prospective, Randomized, Double Blind Investigation of Amnios™ RT for the Treatment of Plantar Fasciitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Globus Medical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Globus Medical Inc</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate clinical outcomes of patients with plantar fasciitis&#xD;
      following treatment with Amnios™ RT. Patients will be randomized to either Amnios™ RT or a&#xD;
      placebo control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analog Scale (VAS) Foot Pain Score</measure>
    <time_frame>3 Months</time_frame>
    <description>The visual analog scale (VAS) is a patient questionnaire used to quantify a subjective experience, such as the intensity of pain. The scale is a 100mm line labeled with &quot;no pain&quot; on the left border and &quot;most intense pain imaginable&quot; on the right border. The subject is instructed to place a vertical line on the scale that indicates the pain severity experienced; 0mm is equal to no pain and 100mm is most intense pain imaginable. Study staff records the distance of the patient's mark on the scale in millimeters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>The occurrence of serious adverse events that are related to the product.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Plantar Fasciitis</condition>
  <arm_group>
    <arm_group_label>Amnios™ RT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Amnios™ RT</intervention_name>
    <description>Acellular human allograft</description>
    <arm_group_label>Amnios™ RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Sterile saline</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of unilateral plantar fasciitis for ≥ 1 month (30 days) and ≤ 18&#xD;
             months by the Investigator&#xD;
&#xD;
          -  VAS Foot Pain score of at least 45mm (out of 100mm scale) at randomization&#xD;
&#xD;
          -  Plantar fasciitis with conservative treatment for ≥ 1 month (30 days), including any&#xD;
             of the following modalities:&#xD;
&#xD;
               -  RICE&#xD;
&#xD;
               -  Stretching exercises&#xD;
&#xD;
               -  NSAIDs&#xD;
&#xD;
               -  Orthotics&#xD;
&#xD;
          -  Diagnostic radiograph within 6 months of enrollment showing view of calcaneus, without&#xD;
             evidence of calcaneal fracture or structural abnormalities&#xD;
&#xD;
          -  BMI ≤ 40 kg/m2&#xD;
&#xD;
          -  Age ≥ 18 years and &lt; 80 years&#xD;
&#xD;
          -  Willing and able to comply with the follow-up requirements of the protocol&#xD;
&#xD;
          -  Signed an Informed Consent Form specific to this research and agreed to release of&#xD;
             medical information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior surgery or trauma resulting in severe, permanent damage to the affected foot&#xD;
&#xD;
          -  Require bilateral plantar fasciitis treatment at time of enrollment (with exception of&#xD;
             compensatory symptoms on the non-affected foot)&#xD;
&#xD;
          -  Prior use of any lower limb injection therapy, including corticosteroids or PRP in&#xD;
             either foot within the last 3 months&#xD;
&#xD;
          -  Has Type I or Type II diabetes mellitus&#xD;
&#xD;
          -  Systemic disorders associated with enthesopathy (disorder of entheses, i.e. bone&#xD;
             attachments) such as Gout, reactive arthritis, rheumatoid arthritis, etc.&#xD;
&#xD;
          -  The presence of diagnosed comorbidities that can be confused with or can exacerbate&#xD;
             the condition (as assessed by radiograph) including:&#xD;
&#xD;
               -  Calcaneal stress fracture&#xD;
&#xD;
               -  Nerve entrapment syndrome (diagnosed as Baxter Nerve Syndrome)&#xD;
&#xD;
               -  Fat pad atrophy (relative to expectations for patient's age)&#xD;
&#xD;
               -  Acute traumatic rupture of the plantar fascia&#xD;
&#xD;
               -  Calcaneal tumor&#xD;
&#xD;
               -  Tarsal tunnel syndrome (diagnosed)&#xD;
&#xD;
               -  Significant bone deformity of the foot that may interfere with the study&#xD;
&#xD;
               -  Other malignant tumors in the foot or conditions that may affect study outcomes&#xD;
&#xD;
          -  Affected site exhibits clinical signs and symptoms of infection of the foot in&#xD;
             question&#xD;
&#xD;
          -  Known allergy or known sensitivity to aminoglycosides&#xD;
&#xD;
          -  Non-ambulatory&#xD;
&#xD;
          -  History of more than 14 days of treatment with immuno-suppressants (including systemic&#xD;
             corticosteroids) or cytotoxic chemotherapy within 30 days prior to enrollment, or who&#xD;
             are anticipated to require such medications during the course of the study&#xD;
&#xD;
          -  Prior radiation at the site, with exception of diagnostic radiographs&#xD;
&#xD;
          -  Use of any investigational drug(s) or investigational therapeutic device(s) within 3&#xD;
             months preceding enrollment&#xD;
&#xD;
          -  Immune disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia, Acquired&#xD;
             Immunodeficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV)&#xD;
&#xD;
          -  History of any condition (including drug or alcohol abuse, medical or psychiatric&#xD;
             condition) that is likely to impair understanding of or compliance with the study&#xD;
             protocol, in the judgment of the Investigator&#xD;
&#xD;
          -  Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women&#xD;
             of childbearing potential who are planning to become pregnant during the time of the&#xD;
             study OR are unwilling/unable to use acceptable methods of contraception (birth&#xD;
             control pills, barriers, or abstinence)&#xD;
&#xD;
          -  Prisoner&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacqueline Myer</last_name>
    <phone>610-930-1800</phone>
    <email>jmyer@globusmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bio-X-Cell Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam Cornell</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Fasciitis, Plantar</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

